Potential Uses of Sacubitril/Valsartan: Need for Data on Efficacy and Safety

被引：0

作者：

Fabien Huet

Mariama Akodad

Eran Kalmanovitch

Jerome Adda

Audrey Agullo

Pascal Batistella

Camille Roubille

François Roubille

机构：

[1] Hôpital Arnaud de Villeneuve,Département de Cardiologie

[2] CHU de Montpellier,Department of Internal Medicine and Hypertension

[3] UFR de Médecine,undefined

[4] Université Montpellier 1,undefined

[5] PhyMedExp,undefined

[6] University of Montpellier,undefined

[7] INSERM U1046,undefined

[8] CNRS,undefined

[9] UMR 9214,undefined

[10] Montpellier University Hospital,undefined

来源：

American Journal of Cardiovascular Drugs | 2019年 / 19卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers have been the cornerstone for the treatment of heart failure (HF) with reduced ejection fraction for decades. According to recent and promising studies, sacubitril/valsartan (SV) might be efficient in alternative indications in the area of HF with preserved left ventricular ejection fraction, chronic kidney disease, and so on. This review briefly summarizes these promising therapeutic options regarding SV and the potential limits and pitfalls for its use in routine practice (due to cognitive uncertainties).

引用

页码：1 / 10

页数：9

共 50 条

[21] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
Takigami, Yu
Ishii, Shunsuke
Eda, Yuko
Yazaki, Mayu
Fujita, Teppei
Iida, Yuichiro
Ikeda, Yuki
Nabeta, Takeru
Oikawa, Jun
Koitabashi, Toshimi
Ako, Junya
HEART AND VESSELS, 2023, 38 (11) : 1337 - 1343
[22] The efficacy and safety of Sacubitril/Valsartan in the treatment of chronic heart failure: a meta-analysis
Zheng, Caiyun
Dai, Hengfen
Huang, Jungao
Lin, Meimei
Zheng, Qiaowen
Tang, Pujing
Xiao, Jingwen
Zhang, Yan
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2021, 13 (11): : 12114 - 12128
[23] The efficacy and safety of sacubitril/valsartan in heart failure with reduced ejection fraction patients with hypotension
Yu Takigami
Shunsuke Ishii
Yuko Eda
Mayu Yazaki
Teppei Fujita
Yuichiro Iida
Yuki Ikeda
Takeru Nabeta
Jun Oikawa
Toshimi Koitabashi
Junya Ako
Heart and Vessels, 2023, 38 : 1337 - 1343
[24] Potential Markers of Sacubitril-Valsartan Tolerance
Ramirez, Gabrielle L.
Nicklas, Todd
Fink, Matthew
Margulies, Kenneth
JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S61 - S62
[25] Efficacy and Safety of Sacubitril/Valsartan in Chronic Type B Aortic Dissection Combined With Mild Hypertension
Wang, Xuelin
Song, Feier
Jiang, Lujing
Huang, Ziling
Luo, Songyuan
Li, Xin
He, Xuyu
AMERICAN JOURNAL OF HYPERTENSION, 2024, 37 (08) : 612 - 620
[26] The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis
Zhou, Wei
Yang, Xinyue
Jin, JingJing
Cheng, Meijuan
Li, Yajing
Bai, Yaling
Xu, Jinsheng
INTERNATIONAL UROLOGY AND NEPHROLOGY, 2024, 56 (01) : 181 - 190
[27] The safety of sacubitril/valsartan in the geriatric heart failure patients
Alharthi, M. Maha
Bakhsh, A.
Alawwad, M.
EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 138 - 138
[28] The efficacy and safety of sacubitril/valsartan in chronic kidney disease: a systematic review and meta-analysis
Wei Zhou
Xinyue Yang
JingJing Jin
Meijuan Cheng
Yajing Li
Yaling Bai
Jinsheng Xu
International Urology and Nephrology, 2024, 56 : 181 - 190
[29] Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Senni, M.
Alemayehu, W.
Sim, D.
Edelmann, F.
Butler, J.
Ezekowitz, J. A.
Hernandez, A. F.
Lam, C. S. P.
O'Connor, C. M.
Pieske, B.
Ponikowski, P.
Roessig, L.
Voors, A. A.
McMullan, C.
Armstrong, P. W.
EUROPEAN HEART JOURNAL, 2021, 42 : 788 - 788
[30] EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN IN PATIENTS WITH STAGE 3B-5 CKD AND HYPERTENSION
Zhou, Qin
Yu, Wenjuan
Shao, Xiaofei
Liu, Qin
Wang, Honglei
Chen, Junzhe
Tang, Ying
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I665 - I667

← 1 2 3 4 5 →